
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

SCHEDULE TO
Tender Offer Statement under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934

(Amendment No. 1)

ALERE INC.
(Name of Subject Company)

ABBOTT LABORATORIES
(Offeror)
(Names of Filing Persons)

SERIES B CONVERTIBLE PERPETUAL PREFERRED STOCK, \$0.001 PAR VALUE
(Title of Class of Securities)

01449J204
(CUSIP Number of Class of Securities)

Hubert L. Allen
Abbott Laboratories
100 Abbott Park Road
Abbott Park, Illinois 60064-6100
Telephone: (224) 667-6100
(Name, address, and telephone number of person authorized to receive notices
and communications on behalf of filing person)

Copies to:
Richard B. Aftanas, P.C.
Ross M. Leff
Kirkland & Ellis LLP
601 Lexington Avenue
New York, New York 10022
Telephone: (212) 446-4800

CALCULATION OF FILING FEE

Transaction valuation*	Amount of filing fee**
\$716,032,371.40	\$82,988.15

* Estimated for purposes of calculating the filing fee only. The transaction valuation was calculated by multiplying 1,774,407 shares of Series B Convertible Perpetual Preferred Stock, par value \$0.001 per share (the "Preferred Stock"), of Alere Inc. ("Alere") outstanding by the offer price of \$402.00 per share of Preferred Stock, plus accrued but unpaid dividends due on the Preferred Stock. The transaction value is also based on an estimate of \$2,720,757.40 of accrued but unpaid dividends on the Preferred Stock as of August 31, 2017.

** The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 1 for Fiscal Year 2017, issued August 31, 2016, by multiplying the Transaction Valuation by 0.0001159.

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

- third-party tender offer subject to Rule 14d-1.
- issuer tender offer subject to Rule 13e-4.
- going-private transaction subject to Rule 13e-3.
- amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

This Amendment No. 1 (this "Amendment") amends and supplements the Tender Offer Statement on Schedule TO initially filed with the United States Securities and Exchange Commission on July 17, 2017 (together with any amendments and supplements thereto, the "Schedule TO") relating to the offer by Abbott Laboratories, an Illinois corporation ("Abbott"), to purchase for cash all of the outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc., par value \$0.001 per share (the "Preferred Stock"), at a purchase price of \$402.00 per share of Preferred Stock (the "Offer Price"), plus accrued but unpaid dividends to, but not including, the settlement date of the Offer, net to the seller thereof in cash, without interest thereon and subject to any withholding taxes required by applicable law, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated as of July 17, 2017 (as it may be amended or supplemented from time to time, the "Offer to Purchase"), and the related Letter of Transmittal (as it may be amended or supplemented from time to time, the "Letter of Transmittal," which, together with the Offer to Purchase, collectively constitute the "Offer"), copies of which are attached as Exhibits (a)(1)(A) and (a)(1)(B), respectively, to the Schedule TO.

All the information set forth in the Offer to Purchase, including Schedule I thereto, is incorporated herein by reference in response to Items 1 through 9 and Item 11 of the Schedule TO, except that such information is amended and supplemented to the extent specifically provided in this Amendment. Capitalized terms used and not otherwise defined in this Amendment shall have the meanings assigned to such terms in the Offer to Purchase on in the Schedule TO.

Items 1, 4 and 11. Summary Term Sheet; Terms of the Transaction; Additional Information.

Items 1, 4 and 11 of the Schedule TO are hereby amended and supplemented by adding the following text thereto:

On August 14, 2017, Abbott announced an extension of the Offer to 11:59 p.m., New York City time, on August 31, 2017, unless the Offer is further extended or earlier terminated in accordance with the terms thereof. The Offer was previously scheduled to expire at 11:59 p.m., New York City time, on August 11, 2017.

The Depositary has advised Abbott that, as of 11:59 p.m., New York City time, on August 11, 2017, greater than 90% of the issued and outstanding shares of Preferred Stock had been validly tendered pursuant to the Offer and not properly withdrawn.

The full text of the press release issued by Abbott announcing the extension of the Offer is attached hereto as Exhibit (a)(5)(A) and is incorporated by reference herein.

In addition, on August 21, 2017, Abbott sent holders the supplemental letter attached as Exhibit (a)(5)(B) hereto, which is incorporated by reference herein.

Item 12. Exhibits

Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibits:

(a)(5)(A) Press Release issued by Abbott Laboratories on August 14, 2017.

(a)(5)(B) Supplemental Letter to Holders, dated as of August 21, 2017.

Amendments to the Offer to Purchase and the Other Exhibits to the Schedule TO

All references to "11:59 p.m., New York City time, on August 11, 2017" in the Offer to Purchase (Exhibit (a)(1)(A) to the Schedule TO), Letter of Transmittal (Exhibit (a)(1)(B) to the Schedule TO), Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (Exhibit (a)(1)(C) to the Schedule TO) and Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (Exhibit (a)(1)(D) to the Schedule TO) are hereby amended and replaced with "11:59 p.m., New York City time, on August 31, 2017". The Offer to Purchase and Items 1 through 9 and 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in any of the foregoing exhibits, are hereby amended and supplemented to reflect the same.

SIGNATURES

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Abbott Laboratories

By: /s/ BRIAN B. YOOR

Name: Brian B. Yoor
Title: *Executive Vice President, Finance and
Chief Financial Officer*

Date: August 21, 2017

INDEX TO EXHIBITS

<u>Exhibit No.</u>	<u>Description</u>
(a)(1)(A)*	Offer to Purchase, dated as of July 17, 2017.
(a)(1)(B)*	Letter of Transmittal.
(a)(1)(C)*	Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
(a)(1)(D)*	Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
(a)(1)(E)*	Form of Summary Advertisement published in the Wall Street Journal on July 17, 2017.
(a)(1)(F)*	Press Release issued by Abbott Laboratories on July 17, 2017.
(a)(5)(A)	Press Release issued by Abbott Laboratories on August 14, 2017.
(a)(5)(B)	Supplemental Letter to Holders, dated as of August 21, 2017.
(d)(1)	Agreement and Plan of Merger, dated as of January 30, 2016, by and among Alere Inc. and Abbott Laboratories (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Abbott Laboratories with the SEC on February 2, 2017).
(d)(2)	Amendment to Agreement and Plan of Merger, dated as of April 13, 2017, by and among Alere Inc., Abbott Laboratories and Angel Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Abbott Laboratories with the SEC on April 14, 2017).

* Previously filed.

QuickLinks

[Item 12. Exhibits](#)

[SIGNATURES](#)

[INDEX TO EXHIBITS](#)



Abbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc.

ABBOTT PARK, Ill., Aug. 14, 2017 — Abbott announced today that it is extending its previously announced tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock (the “Preferred Stock”) of Alere Inc. (“Alere”) at a price of \$402.00 per share of Preferred Stock, plus accrued but unpaid dividends to, but not including, the settlement date of the tender offer, net to the seller thereof in cash, without interest thereon and subject to any withholding of taxes required by applicable law (the “Offer”). The Offer is being made pursuant to an Offer to Purchase, dated July 17, 2017 (the “Offer to Purchase”), and in connection with Abbott’s previously announced agreement to acquire Alere (the “Merger”). The Merger is not conditioned upon, or otherwise subject to, the completion of the Offer.

The Offer is being extended to allow additional time for the consummation of the Merger, which is a condition to the completion of the Offer. The Offer was previously scheduled to expire at 11:59 p.m., New York City time, on Friday, Aug. 11, 2017 and will now expire at 11:59 p.m., New York City time, on Thursday, Aug. 31, 2017 (such date and time, as it may be extended or earlier terminated, the “Expiration Date”). If, at the Expiration Date, any of the conditions to the Offer have not been satisfied or waived, Abbott may elect to further extend the Offer for any length of time and in its sole discretion, but is under no obligation to do so.

American Stock Transfer & Trust Company, LLC, the depository for the Offer, has advised Abbott that, as of 11:59 p.m., New York City time, on Friday, Aug. 11, 2017, greater than 90% of the issued and outstanding shares of Preferred Stock had been tendered in the Offer. Holders of Preferred Stock who have already tendered their shares do not have to re-tender their shares or take any other action as a result of the extension of the expiration of the Offer.

-more-

For more information, contact Barclays Capital Inc., the Dealer-Manager for the Offer, or D.F. King & Co., Inc., the Information Agent for the Offer.

D.F. King & Co., Inc.
48 Wall Street — 22nd Floor
New York, New York 10005

Banks and Brokers Call: (212) 269-5550
All others call Toll-Free: (877) 283-0316
Email: alr@dfking.com

Barclays
745 Seventh Avenue, 5th Floor
New York, New York 10019
Attn: Liability Management Group

Banks and Brokers Call: (212) 528-7581
All others call Toll-Free: (800) 438-3242

Additional Information and Where to Find It

This announcement is neither an offer to purchase nor a solicitation of an offer to sell securities. The Offer for the outstanding shares of Alere’s Preferred Stock described in this news release is being made pursuant to an Offer to Purchase and related materials that Abbott has filed with the Securities and Exchange Commission (the “SEC”) pursuant to a Schedule TO. The Schedule TO, Offer to Purchase, a related letter of transmittal and other Offer documents contain important information that should be read carefully before any decision is made with respect to the Offer. These materials (and all other documents Abbott has filed with the SEC) will be available at no charge on the SEC’s website at www.sec.gov.

About Abbott

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 94,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at [@AbbottNews](https://twitter.com/AbbottNews).

A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” in Abbott’s Annual Report on Form 10-K for the year ended Dec. 31, 2016, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Abbott Media:

Darcy Ross, +1 (224) 667-3655

Elissa Maurer, +1 (224) 668-3309

Abbott Financial:

Scott Leinenweber, +1 (224) 668-0791

Michael Comilla, +1 (224) 668-1872

###

3

**Supplemental Letter to Holders Relating to the
Offer to Purchase for Cash
All Outstanding Shares of Series B Convertible Perpetual Preferred Stock**

of

Alere Inc.

at

\$402.00 Net Per Share of Series B Convertible Perpetual Preferred Stock

by

Abbott Laboratories

**THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT
11:59 P.M., NEW YORK CITY TIME, ON AUGUST 31, 2017,
UNLESS THE OFFER IS EXTENDED OR EARLIER TERMINATED
(SUCH DATE AND TIME, AS IT MAY BE EXTENDED OR EARLIER TERMINATED, THE "EXPIRATION DATE").**

As set forth in its Offer to Purchase, dated as of July 17, 2017 (the "Offer to Purchase"), Abbott Laboratories, an Illinois corporation ("Abbott," "we" or "us"), is offering to purchase all of the outstanding shares of Series B Convertible Perpetual Preferred Stock, par value \$0.001 per share (the "Preferred Stock"), of Alere Inc., a Delaware corporation ("Alere"), issued pursuant to the Certificate of Designations, Preferences and Rights of Series B Convertible Perpetual Preferred Stock (the "Certificate of Designations"), at a price of \$402.00 per share of Preferred Stock, plus accrued but unpaid dividends to, but not including, the Tender Settlement Date (as defined herein), net to the seller thereof in cash, without interest thereon and subject to any withholding of taxes required by applicable law, upon the terms and subject to the conditions set forth in the Offer to Purchase (this "Offer").

Abbott is providing this supplemental letter to holders of Preferred Stock to encourage holders to tender their shares of Preferred Stock in this Offer. Holders should review the Offer to Purchase, which contains all of the material terms and conditions of this Offer. This supplemental letter does not, and is not intended to, amend, alter, modify or otherwise change any of the terms of this Offer set forth in the Offer to Purchase, which, other than with respect to the extension of the Expiration Date described in the immediately preceding paragraph, remain unchanged.

Abbott and Alere are party to an Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017, providing for the acquisition of Alere by Abbott (the "Merger"), with Alere surviving the Merger as a wholly-owned subsidiary of Abbott. The Merger is not conditioned upon, or otherwise subject to, the completion of this Offer. This Offer, however, is conditioned upon the consummation of the Merger.

On August 14, 2017, Abbott announced that it had extended the Expiration Date of this Offer to 11:59 p.m., New York City time, on August 31, 2017 in order to allow additional time for the consummation of the Merger. American Stock Transfer & Trust Company, LLC, the depository for this Offer, has advised Abbott that, as of 11:59 p.m., New York City time, on Friday, August 11, 2017, greater than 90% of the issued and outstanding shares of Preferred Stock had been tendered in this Offer.

SUMMARY OF KEY DATES & TERMS

Securities Sought:	All outstanding shares of Series B Convertible Perpetual Preferred Stock, par value \$0.001 per share, of Alere Inc. (the "Preferred Stock")
Price Offered Per Share:	\$402.00 per share of Preferred Stock, plus accrued and unpaid dividends to, but not including, the Tender Settlement Date (as defined herein), net to you in cash, without interest thereon, subject to any withholding of taxes required by applicable law
Launch of Offer	July 17, 2017
Scheduled Expiration of Offer:	11:59 p.m., New York City time, on August 31, 2017, unless extended or earlier terminated
Scheduled Closing of Offer:	As soon as practicable following the Expiration Date (the "Tender Settlement Date")
The Purchaser:	Abbott Laboratories

* * * * *

What options are available to you in connection with the Merger and this Offer?

You may:

1. tender your shares of Preferred Stock to Abbott pursuant to the terms of this Offer;
2. convert your shares of Preferred Stock in connection with the Merger pursuant to the terms of the Certificate of Designations; or
3. retain your shares of Preferred Stock and continue to hold such shares following the consummation of the Merger.

If you convert your shares of Preferred Stock in connection with the Merger, you may not separately tender such shares of Preferred Stock in this Offer.

How much is Abbott offering to pay for the shares of Preferred Stock and what is the form of payment? Will I have to pay any fees or commissions?

Set forth below is a summary of the per-share consideration expected to be paid to you under each of the options noted above:

1. If You Tender in this Offer: \$402.00 per share plus accrued but unpaid dividends (liquidation preference of \$400.00 per share, plus a premium of \$2.00 per share)
2. If You Convert in Connection with the Merger: maximum of \$400.00 per share plus accrued but unpaid dividends
3. If You Continue to Hold Shares of Preferred Stock: \$294.29 per share plus accrued but unpaid dividends (only in limited circumstances and absent a subsequent Fundamental Change, as specified in the Certificate of Designations)

If you are the record owner of your shares of Preferred Stock and you tender your shares of Preferred Stock to us in this Offer, you will not have to pay brokerage fees, commissions or similar expenses. If you own your shares of Preferred Stock through a broker or other nominee and your broker or other nominee tenders your shares of Preferred Stock on your behalf, your broker or nominee may charge a fee for doing so. You should consult your broker or nominee to determine whether any charges will apply. See Section 1—"Terms of the Offer" and Section 2—"Acceptance for Payment and Payment for Shares of Preferred Stock" of the Offer to Purchase for more information.

Who can you talk to if you have questions about this Offer?

You may call D.F. King & Co., Inc., the Information Agent for this Offer, Toll-Free at (212) 269-5550 or (877) 283-0316, or Barclays Capital Inc., the Dealer-Manager for this Offer, Toll-Free at (212) 528-7581 or (800) 438-3242.

The Information Agent for this Offer is:

D.F. King & Co., Inc.

48 Wall Street, 22nd Floor
New York, New York 10005

Banks and Brokers Call: (212) 269-5550
All others call Toll-Free: (877) 283-0316
Email: alr@dfking.com

The Dealer-Manager for this Offer is:

Barclays Capital Inc.

745 Seventh Avenue, 5th Floor
New York, New York 10019
Attn: Liability Management Group

Banks and Brokers Call: (212) 528-7581
All others call Toll-Free: (800) 438-3242

QuickLinks

[Exhibit 99.\(a\)\(5\)\(B\)](#)

[Supplemental Letter to Holders Relating to the Offer to Purchase for Cash All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at \\$402.00 Net Per Share of Series B Convertible Perpetual Preferred Stock by Abbott Laboratories THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M., NEW YORK CITY TIME, ON AUGUST 31, 2017, UNLESS THE OFFER IS EXTENDED OR EARLIER TERMINATED \(SUCH DATE AND TIME, AS IT MAY BE EXTENDED OR EARLIER TERMINATED, THE "EXPIRATION DATE"\).](#)
[SUMMARY OF KEY DATES & TERMS](#)